On August 13, INSILICO rose 5.09% in regular trading, trading at 48.32 HKD/share, with turnover of HKD 318 million. The rally was driven by the announcement of a new research collaboration with Korean firm THPharm, adding to the company's intensifying pace of commercial partnership deals.

The THPharm collaboration marks the latest in a series of partnership milestones. JPMorgan disclosed on August 7 that it acquired 1.83 million shares at an average price of HKD 43.61, raising its long position to 5.1%. Guotai Haitong Securities also initiated coverage with an Overweight rating and a target price of HKD 73.23, citing the company's leading position in AI-driven drug discovery with end-to-end capabilities. Additionally, the company's board is scheduled to convene on August 26 to review interim results for the first half of the year.

Within the Life Sciences Tools & Services sector, peer stocks showed broad strength, with GENSCRIPT BIO up 6.6%, PHARMARON up 5.38%, XTALPI up 2.62%, WUXI APPTEC up 2.56%, and WUXI BIO up 1.71%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)